GB201215289D0 - Nanoparticle formulation - Google Patents

Nanoparticle formulation

Info

Publication number
GB201215289D0
GB201215289D0 GBGB1215289.8A GB201215289A GB201215289D0 GB 201215289 D0 GB201215289 D0 GB 201215289D0 GB 201215289 A GB201215289 A GB 201215289A GB 201215289 D0 GB201215289 D0 GB 201215289D0
Authority
GB
United Kingdom
Prior art keywords
nanoparticle formulation
nanoparticle
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1215289.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Ip2ipo Innovations Ltd
Original Assignee
Medical Research Council
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council, Imperial Innovations Ltd filed Critical Medical Research Council
Priority to GBGB1215289.8A priority Critical patent/GB201215289D0/en
Publication of GB201215289D0 publication Critical patent/GB201215289D0/en
Priority to US14/424,332 priority patent/US10201499B2/en
Priority to HK15112861.4A priority patent/HK1211862B/en
Priority to PCT/GB2013/052258 priority patent/WO2014033453A1/en
Priority to AU2013308245A priority patent/AU2013308245B2/en
Priority to CN201380055336.1A priority patent/CN104837482B/zh
Priority to EP13760080.5A priority patent/EP2890365B1/en
Priority to CA2882705A priority patent/CA2882705C/en
Priority to JP2015529120A priority patent/JP6483017B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1215289.8A 2012-08-28 2012-08-28 Nanoparticle formulation Ceased GB201215289D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1215289.8A GB201215289D0 (en) 2012-08-28 2012-08-28 Nanoparticle formulation
US14/424,332 US10201499B2 (en) 2012-08-28 2013-08-28 Nanoparticle formulation
HK15112861.4A HK1211862B (en) 2012-08-28 2013-08-28 Nanoparticle formulation
PCT/GB2013/052258 WO2014033453A1 (en) 2012-08-28 2013-08-28 Nanoparticle formulation
AU2013308245A AU2013308245B2 (en) 2012-08-28 2013-08-28 Nanoparticle formulation
CN201380055336.1A CN104837482B (zh) 2012-08-28 2013-08-28 纳米颗粒制剂
EP13760080.5A EP2890365B1 (en) 2012-08-28 2013-08-28 Nanoparticle formulation
CA2882705A CA2882705C (en) 2012-08-28 2013-08-28 Nanoparticle formulation comprising cationic cholesterol derivatives for delivery of short-chain fatty acids
JP2015529120A JP6483017B2 (ja) 2012-08-28 2013-08-28 ナノ粒子製剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1215289.8A GB201215289D0 (en) 2012-08-28 2012-08-28 Nanoparticle formulation

Publications (1)

Publication Number Publication Date
GB201215289D0 true GB201215289D0 (en) 2012-10-10

Family

ID=47045497

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1215289.8A Ceased GB201215289D0 (en) 2012-08-28 2012-08-28 Nanoparticle formulation

Country Status (8)

Country Link
US (1) US10201499B2 (enExample)
EP (1) EP2890365B1 (enExample)
JP (1) JP6483017B2 (enExample)
CN (1) CN104837482B (enExample)
AU (1) AU2013308245B2 (enExample)
CA (1) CA2882705C (enExample)
GB (1) GB201215289D0 (enExample)
WO (1) WO2014033453A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
SG10201907660YA (en) 2015-01-23 2019-10-30 Univ Temple Use of short chain fatty acids in cancer prevention
CN111759823B (zh) * 2015-09-17 2022-12-30 阿赖耶识（上海）生物技术有限公司 一种高稳定的非囊泡型纳米颗粒及其在治疗微生物感染中的应用
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
CN110475551A (zh) 2017-01-27 2019-11-19 英联邦高等教育系统天普大学 使用短链脂肪酸治疗和预防疾病和障碍
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
WO2018169954A1 (en) 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
WO2018195067A1 (en) 2017-04-17 2018-10-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
CN107049954A (zh) * 2017-06-12 2017-08-18 杭州普施康生物科技有限公司 一种药物组合及其制备方法和用途
CN110192651A (zh) * 2019-05-31 2019-09-03 浙江工业大学 一种利用大豆分离蛋白负载植物甾醇酯的纳米乳液的制备方法
CN111426659B (zh) * 2020-03-24 2023-06-06 深圳唯公生物科技有限公司 磁性荧光编码微球及其制备方法
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
WO2023205810A2 (en) * 2022-04-22 2023-10-26 University Of Virginia Patent Foundation Nano-enhanced vaccine
WO2024102902A1 (en) * 2022-11-10 2024-05-16 Temple University-Of The Commonwealth System Of Higher Education Methods of treating or preventing liver diseases or disorders
CN118105524B (zh) * 2024-03-14 2024-11-22 南京鼓楼医院 一种靶向肠上皮细胞的焦亡抑制剂药物递送系统及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
WO1997045442A1 (en) * 1996-05-24 1997-12-04 Imperial College Of Science Technology And Medicine Polycationic sterol derivatives as transfection agents
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
IT1303787B1 (it) * 1998-11-25 2001-02-23 Maria Rosa Gasco "nanosfere lipidiche solide atte ad una rapida internalizzazione nellecellule"
WO2000035422A2 (en) 1998-12-18 2000-06-22 Hadasit Medical Research Services & Development Ltd. Method of administering a compound to multi-drug resistant cells
US6387952B1 (en) 2000-09-19 2002-05-14 Arco Chemical Technology L.P. Method of treating gastrointestinal disorders, particularly colitis
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
US20090123388A1 (en) 2005-01-14 2009-05-14 Medical College Of Georgia Research Institute Prodrugs of Short-Chain Fatty Acids and Treatment Methods
US9315532B2 (en) * 2005-05-24 2016-04-19 The Johns Hopkins University Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof
ITMI20051024A1 (it) 2005-06-01 2006-12-02 Maria Rosa Gasco Nuovo uso di nanoparticelle lipidiche solide
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2673622A1 (en) 2006-12-22 2008-07-03 Imuthes Limited Lipid
EP2350296A4 (en) 2008-11-17 2013-04-03 Enzon Pharmaceuticals Inc BRANCHED CATIONIC LIPIDS FOR THE SYSTEM FOR INTRODUCING NUCLEIC ACIDS

Also Published As

Publication number Publication date
US20150224054A1 (en) 2015-08-13
JP6483017B2 (ja) 2019-03-13
AU2013308245B2 (en) 2018-03-29
CA2882705A1 (en) 2014-03-06
US10201499B2 (en) 2019-02-12
JP2015530382A (ja) 2015-10-15
CN104837482A (zh) 2015-08-12
CN104837482B (zh) 2018-09-18
EP2890365A1 (en) 2015-07-08
AU2013308245A1 (en) 2015-04-09
EP2890365B1 (en) 2019-11-20
WO2014033453A1 (en) 2014-03-06
CA2882705C (en) 2021-06-22
HK1211862A1 (en) 2016-06-03

Similar Documents

Publication Publication Date Title
IL254716B (en) Zinc-lysine conjugate
IL235966A0 (en) Antibody formulation
IL233530A0 (en) cosmetic
PL3181128T3 (pl) Kompozycja farmaceutyczna nilotynibu
SG11201503403QA (en) Encapsulated Nanoparticles
ZA201306000B (en) Stable formulation
ZA201409020B (en) Pharmaceutical formulation
SG11201501382YA (en) Nanoparticulate contrast agent
ZA201407677B (en) Nicotine formulation
EP2821058A4 (en) COSMETIC
GB201216930D0 (en) Nanoparticles
EP2821059A4 (en) COSMETIC
EP2839835A4 (en) ENCAPSULATED FORMULATION
GB201209517D0 (en) Nanoparticles
ZA201408114B (en) Oral formulation
GB201211247D0 (en) Improved formulation
GB201211773D0 (en) Coated nanoparticle
GB201206178D0 (en) Formulations
IL234771A0 (en) Nicotine formulation
GB201222922D0 (en) Topical formulation
GB201210088D0 (en) Odontalgic preparation
GB201214749D0 (en) Compounds and their uses
GB201216165D0 (en) Virtues iBrush
GB201220595D0 (en) Keysafe application
GB201212876D0 (en) Pramella

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)